Transactions

Catalyst Pharmaceuticals, Inc.’s acquisition of commercial rights to FYCOMPA From Eisai Co., Ltd.

Date Announced:
12/19/2022

client:
Catalyst Pharmaceuticals, Inc.

Status:
Pending

Value:
$160 million plus milestones and royalties

Clear all

Download CSV